The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics
Open accessAbstract
A main challenge in realizing the full potential of nucleic acid therapeutics is efficient delivery of them into targeted tissues and cells. N-acetylgalactosamine (GalNAc) is a well-defined liver-targeted moiety benefiting from its high affinity with asialoglycoprotein receptor (ASGPR). By conjugating it directly to the oligonucleotides or decorating it to a certain delivery system as a targeting moiety, GalNAc has achieved compelling successes in the development of nucleic acid therapeutics in recent years. Several oligonucleotide modalities are undergoing pivotal clinical studies, followed by a blooming pipeline in the preclinical stage. This review covers the progress of GalNAc-decorated oligonucleotide drugs, including siRNAs, anti-miRs, and ASOs, which provides a panorama for this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA biogenesis: coordinated cropping and dicing
Kim, V. N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1644 · Cited by 2,546
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D., Tolcher, A., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,505
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Endosomal escape pathways for delivery of biologicals
Varkouhi, A. K., Scholte, M., Storm, G., & Haisma, H. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.004 · Cited by 1,561 · cited 1×
“Protonation further leads to inflow of H and Cl and water into the endosomes, resulting in osmotic swelling and endosome rupture.(88) As a result, siRNAs successfully release from the endosome and/or lysosome and trigger RNAi.”
BackgroundCoated pits, coated vesicles, and receptor-mediated endocytosis
Goldstein, J. L., Anderson, R. G. W., & Brown, M. S. (1979) · Nature · doi:10.1038/279679a0 · Cited by 1,532
Ashwell, G., & Morell, A. G. (1974) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470122860.ch3 · Cited by 1,210
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
RNAi therapeutics: a potential new class of pharmaceutical drugs
Bumcrot, D., Manoharan, M., Koteliansky, V., & Sah, D. W. Y. (2006) · Nature Chemical Biology · doi:10.1038/nchembio839 · Cited by 1,085
Illuminating the silence: understanding the structure and function of small RNAs
Rana, T. M. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2085 · Cited by 1,083
Cited by
Therapeutic siRNA: state of the art
Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X.-J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0207-x · Cited by 1,586
Self-citationEmerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics
Springer, A. D., & Dowdy, S. F. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0736 · Cited by 711
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Shen, X., & Corey, D. R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 632
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
Ahn, G., Banik, S. M., Miller, C. L., Riley, N. M., Cochran, J. R., & Bertozzi, C. R. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00770-1 · Cited by 619
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment
Liu, R., Luo, C., Pang, Z., Zhang, J., Ruan, S., Wu, M., Wang, L., Sun, T., Li, N., Han, L., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.05.032 · Cited by 516
Self-citationDelivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
Synthetic materials at the forefront of gene delivery
Lostalé-Seijo, I., & Montenegro, J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0039-1 · Cited by 310
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 298
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X.-J., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 286
Self-citationThe powerful world of antisense oligonucleotides: From bench to bedside
Quemener, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · WIREs RNA · doi:10.1002/wrna.1594 · Cited by 280
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P.-H., AL Fayez, N., Hohenwarter, L., & Li, S.-D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 264
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Improving siRNA Delivery In Vivo Through Lipid Conjugation
Osborn, M. F., & Khvorova, A. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0725 · Cited by 137
RNA delivery biomaterials for the treatment of genetic and rare diseases
Zhao, W., Hou, X., Vick, O. G., & Dong, Y. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119291 · Cited by 82
ASGR1 and its enigmatic relative, CLEC10A
Hoober, J. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144818 · Cited by 74
de Paula Brandão, P. R., Titze-de-Almeida, S. S., & Titze-de-Almeida, R. (2020) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00438-6 · Cited by 72
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Sewing, S., Roth, A. B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., Ploix, C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187574 · Cited by 52
Yenilmez, B., Wetoska, N., Kelly, M., Echeverria, D., Min, K., Lifshitz, L., Alterman, J. F., Hassler, M. R., Hildebrand, S., DiMarzio, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.007 · Cited by 46
Ballman, K. K., Peek, V. L., Sloan, J. H., Li, J., Konrad, R. J., & Wen, Y. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00914-w · Cited by 4
Metadata
- Authors
- Huang, Y.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 6
- Pages
- 116-132
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2563642244
- Cited by
- 291
- References
- 102
- FWCI
- 14.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.